The aim of the study was to investigate the effect of therapy by rilmenidine on endothelial and platelet function in 23 patients with the early stages of untreated essential hypertension. The measurements were carried out before therapy, after 1 week of placebo administration, after 1 week, after 1 month and after 3 months of therapy. After 1 week of therapy both systolic (SBP) and diastolic blood pressure (DBP) were reduced (P Ͻ 0.001) all over the study period. Plasma thrombomodulin (TM) and von Willebrand factor (vWF) as indicators of endothelial dysfunction, and plasma ␤-thromboglobulin (␤TG) as an indicator of in vivo platelet activation, were investigated. Fibrinogen as a risk factor for vascular changes was also assayed. Platelet aggregation without stimulation (spontaneous, SPA) and induced by adre-
Introduction
Hypertension is generally accepted as a risk factor for the development of atherosclerosis and its clinical course is associated with the quite frequent occurrence of arterial thrombosis. Effective control of blood pressure (BP) can nowadays be achieved with a range of antihypertensive agents. However, to simply decrease BP is no longer a sufficient goal for new antihypertensive therapy. The choice of an antihypertensive agent must also be based on the most effective prevention of cardiovascular morbidity and mortality. Not all currently used antihypertensive agents cause a reversal of hypertensioninduced structural cardiovascular changes. Arterial hypertension is accompanied by vascular complications associated with platelet activation and endo-thelium damage. 1, 2 They can contribute to the processes of atherogenesis and intravascular thrombosis. Plasma ␤-thromboglobulin is an established marker of platelet activity, whilst von Willebrand factor (vWF) and soluble thrombomodulin are used to assess the endothelium integrity. They were reported to be increased in uncontrolled essential hypertension. [3] [4] [5] Plasma fibrinogen is one of the well established cardiovascular risk factors for mortality and morbidity. Elevated fibrinogen contributes to plasma hyperviscosity and its higher levels are demonstrated in hypertensives with coronary artery disease. 2, 6 Restoration of endothelial function and reduction of increased platelet aggregation in essential hypertension are one of the aims of modern antihypertensive therapy. Therefore, the effects of the various antihypertensive drugs on endothelial and platelet functions are of interest. Rilmenidine is a new promising centrally acting antihypertensive agent of a second generation with reduced side effects which fulfills all the requirements of a modern antihypertensive drug. Despite the similar profiles, there are important differences between rilmenidine and the first-generation sympatholytics such as clonidine. Rilmenidine is the first oxazoline derivative and its molecular structure differs from imidazoline derivative clonidine. 7 It acts preferably on the newly described I 1 -imidazoline receptor, also having a lesser effect on central ␣ 2 -adrenoceptors. 8 Rilmenidine, a selective I 1 imidazoline receptor binding agent, has been shown to bind to imidazoline receptor in the central nervous system (in the brain stem) and in the kidney. 9 Increased sympathetic activity seems to play an important role in the pathogenesis and development of complications of atherosclerotic origin in patients with essential hypertension. The common features of the centrally acting agents are due to the fact that they all reduce sympathetic nervous system activity.
The aim of the present study was to investigate the effect of 1 week, 1 month, and 3 months therapy by a new antihypertensive agent, rilmenidine, on both endothelial and platelet function in patients with the early stages of essential hypertension. We tested the hypothesis that rilmenidine reduced endothelial and platelet markers over a period of 3 months. The values of these markers after treatment were compared with those without (before) treatment and after placebo administration in the same patients.
Subjects and methods

Subjects
Twenty-three patients, 10 women and 13 men, aged from 20 to 73 years (median 49 years, with 95% confidence interval (CI) of 41-54 years) with untreated essential hypertension at the 1st and 2nd stage according to WHO classification, were investigated. Moreover, a population of 23 sex-and age-matched healthy subjects for assessment of normal values of the markers (Table 1 ) was also examined.
The patients with a new finding of hypertension (not more than 3 months) were included in the study. Arterial hypertension was defined as BP у140 and/or у90 mm Hg. The whole patient population underwent full investigation for secondary hypertension. The diagnosis of essential hypertension was made by physical examination, routine and special laboratory tests, echocardiography, endocrine and radiologic investigations. Patients with evidence of manifest vascular diseases, secondary All the patients had never been treated by antihypertensive agents. Any other drug treatment had been withdrawn for at least 2 weeks before the investigation. Fourteen patients were diagnosed as being in the 1st, and nine in 2nd stage of the disease. The values of their BP without therapy (at the inclusion to the study), after 1 week of placebo administration, and during rilmenidine therapy are shown in Table 2 .
All the patients were started on placebo for a period of 1 week before active treatment. Then they were placed on rilmenidine therapy (TENAXUM  Servier) in a dose of 1 mg once daily. Five and two of these treated patients (non-responders) had to be withdrawn from the complete study and placed on combination therapy after a period of 1 week and 1 month, respectively. All the measurements were carried out without therapy (n = 23), after 1 week of placebo administration (n = 23), and after 1 week (n = 23), after 1 month (n = 18) and after 3 months (n = 16) of rilmenidine therapy.
Laboratory methods
In each of the subjects laboratory markers of endothelial and platelet function were studied. Plasma thrombomodulin (TM) and vWF were used as indicators of endothelial dysfunction and/or damage. Fibrinogen as a risk factor for vascular changes was also investigated. Plasma ␤-thromboglobulin (␤TG), a specific protein of platelet ␣-granules, as an indicator of in vivo platelet activation, and platelet aggregation were measured. Plasma TM was determined by an enzyme immunoassay using a diagnostic Asserachrom Thrombomodulin kit (Diagnostica Stago, France). vWF antigen was measured in plasma by an enzyme immunoassay using a commercially available Asserachrom vWF kit (Diagnostica Stago, France). Plasma fibrinogen level was determined by Turbox Fibrinogen Assay (Orion Diagnostica, Finland), a liquidphase immunoprecipitation and quantitative nephelometric end-point detection with Turbox analyser (Orion Diagnostica, Finland). Plasma ␤TG was assayed by means of a commercial enzyme immunoassay Asserachrom ␤TG kit (Diagnostica Stago, France). Whole blood platelet aggregation was measured without stimulation (spontaneous platelet aggregation, SPA) and after induction of the aggregation reaction by adrenaline (total aggregation, APA). Its procedure has been described in detail in 551 Table 2 Median values of the blood pressure (BP) and laboratory variables investigated, their 95% confidence intervals (in parentheses) in hypertensives without therapy, after 1 week of placebo administration, after 1 week, after 1 month and after 3 months of rilmenidine therapy MAP = mean arterial pressure; SBP = systolic blood pressure; DBP = diastolic blood pressure; SPA = spontaneous platelet aggregation; APA = adrenaline induced platelet aggregation; ␤TG = ␤-thromboglobulin; TM = thrombomodulin; vWF = von Willebrand factor. * P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001 -in comparison with the values before treatment and after placebo administration, respectively. our previous study. 10 All blood collections were carried out between 8.00 and 9.00 am after an overnight fast and an 8-h supine rest, without venous stasis. All measurements of BP and blood collections were made in the supine position, after the patient had rested for 10 min. Blood for TM, vWF and fibrinogen determination was collected using Monovette 9NC tubes of Sarstedt system (Nü mbrecht, Germany). Plasma was separated by centrifugation at 2000 g for 10 min. A portion was immediately frozen at −20°C until tested for the TM and vWF level. The fibrinogen concentration was determined immediately after collection from the remaining sample. Blood for ␤TG assay was collected into a 5.0 ml plastic disposable syringe. An aliquot (4.5 ml) of blood was immediately transferred to a pre-cooled tube (Diatube H) containing a special anticoagulant mixture for platelet markers, supplied by Becton Dickinson (Plymouth, UK). The content was gently stirred, and the tube was placed back to the ice-cold water bath within 2 min from the beginning of blood collection. The tube was allowed to cool in the ice-cold water bath for at least 15 min. Then the blood sample was centrifuged at 2000 g for 30 min at 4°C within the hour. One-third of the mid-layer plateletpoor plasma was then taken to frozen at −20°C, and stored until analysed.
When a sample for ␤TG assay was obtained, 0.9 ml of blood (for platelet aggregation) from the same venipuncture were drawn into a 2.0 ml plastic syringe containing 0.1 ml of 3.8% sodium citrate. The sample was stirred, and one drop of blood from
Journal of Human Hypertension the syringe (for measuring the so-called circulating platelet aggregates) was transferred to a glass slide, spread to make a thin smear, and quickly dried in air. Another 0.2 ml of anticoagulated blood were delivered into a plastic tube to which 0.02 ml of aggregating agent was added. Adrenaline, 1 mg/ml solution (Adrenalin amp, Leciva, Czech Republic) was used for induction of aggregation. Blood collection, sample treatment and procedures for platelet aggregation investigation have been described in our previous study.
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Statistical analysis
Power calculations were used to justify the number of patients in the study. The aim was to determine a test power, ie a probability that a real difference will not be overlooked. Based on the optimal values of BP and laboratory variables in healthy subjects, a minimal relevant effect (␦) was estimated. It was defined at least as their 10% reduction due to antihypertensive therapy. The achieved effect was compared with that considered to be a minimal effect. These calculations showed that ␦ for systolic BP (SBP), diastolic BP (DBP), SPA, APA and ␤TG in treated hypertensives is even significantly better. This effect was not achieved after placebo administration.
The Wilcoxon paired-rank test was used for the evaluation of the differences in the values between the sex-and age-matched healthy subjects and hypertensives. The effect of rilmenidine therapy on
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BP and laboratory variables in hypertensives was evaluated also by the Wilcoxon paired-rank test, since the differences between the groups were tested within the same subject. The graphs were prepared with the GraphPad Prism computer programme (San Diego, USA).
Results
A significant decrease of the BP (MAP as well as SBP and DBP) by rilmenidine therapy was achieved. All the values of BP and significance of their changes are indicated in Table 2 . The MAP decreased from 135 mm Hg (133-140, median and 95% CI) before therapy to 115 mm Hg (108-120.0, P Ͻ 0.001) at the end of the first week of therapy, to 111 mm Hg (105-115, P Ͻ 0.001) after 1 month of therapy, and to 115 mm Hg (105-120, P Ͻ 0.001) after 3 months of therapy. There was not any significant difference between the BP values measured before therapy and after placebo administration. No significant changes between the BP values measured after 1 week, after 1 month, and after 3 months of rilmenidine therapy were found. In comparison with healthy subjects, a statistically significant increase of SPA (P Ͻ 0.01 before placebo, P Ͻ 0.05 after placebo), APA (P Ͻ 0.05), ␤TG (P Ͻ 0.001), vWF (P Ͻ 0.001) and TM (P Ͻ 0.05) in untreated hypertensives (before and after placebo administration) was found. There were no changes of fibrinogen concentration in untreated hypertensives. The values of laboratory variables in a group of sex-and age-matched healthy subjects are shown in Table 1 .
In comparison with the values before therapy, a significant decrease in both SPA and APA after 1 week, after 1 month, and after 3 months of rilmenidine administration was found. A significant decrease of plasma ␤TG level after 3 months of rilmenidine therapy was observed. A significant decrease of vWF antigen concentration in plasma after 1 month, and after 3 months of rilmenidine therapy was found in the hypertensive patients. Changes in platelet aggregation, plasma ␤TG and vWF after rilmenidine therapy are shown in Figure 1 .
However, we failed to find any significant changes of plasma TM and fibrinogen concentration due to rilmenidine therapy. There was no difference between any laboratory parameter investigated before treatment and after placebo administration. Medians and 95% CIs of BP and of all laboratory parameters investigated are shown in Table 2 .
Discussion
Modern antihypertensive therapy has focused not only on BP control but also on the favourable modification of known prognostic indices, such as microalbuminuria, endothelial and platelet dysfunction. Functional changes of endothelium may be involved in the pathogenesis and progression of cardiovascular diseases. Experimental data suggest various interactions of sympathetic nervous system (SNS) with the vascular endothelium. Increased SNS activity is thought to lead to increased BP and to structural and metabolic abnormalities that increase the risk of atherosclerosis. 12 In our study, a significant decrease of plasma vWF antigen level after 1 month and after 3 months of rilmenidine therapy was observed. vWF is the largest plasma protein that mediates platelet activation in the subendothelium of the damaged blood vessels. It is synthesised and stored in endothelial cells and after stimulation or cell damage secreted into the bloodstream. The majority of plasma vWF antigen comes from endothelial cells. Boneu et al 13 were the first to describe vWF as marker of endothelial cell damage. Blann et al 3 were the first to describe raised vWF in essential hypertension, a finding subsequently confirmed by others. 4, [14] [15] [16] [17] In agreement with their results, the increase of vWF in patients with the early stages of essential hypertension compared to healthy subjects was also found in the present study.
Similarly, the results of this study demonstrate the increase of plasma TM, another marker of endothelial cell injury, in hypertensive patients. On the other hand, no changes in plasma TM were found during 3-months treatment by rilmenidine in our patients with the early stages of essential hypertension. The TM is a natural anticoagulant produced by endothelial cells and bound to their surface. It can be cleaved from endothelial cells and released in trace amounts into circulation. Some findings in hypertension suggest that TM is released into the plasma only by true endothelial cell damage during development of vascular complications. 10, 14, [18] [19] [20] . Probably a certain degree of endothelial injury is necessary for its plasma increase. Low levels of plasma TM in precapillary pulmonary hypertension, 553 but high levels in postcapillary pulmonary hypertension (compared with healthy controls) were described. 21 It was shown that BP lowering can be associated with reductions in fibrinogen and soluble TM, 22 but it need not always be followed by this favourable effect. 10, 11 In this study, only hypertensive patients without microalbuminuria were included for investigations. Microalbuminuria is an independent predictor for cardiovascular morbidity and mortality in essential hypertension. It is also a marker of widespread endothelial dysfunction. The results of another study 23 suggest that in hypertensive patients with microalbuminuria, effective 6 months therapy by an imidazoline I 1 -receptor agonist moxonidine significantly reduces urine albumin excretion as well as TM and plasminogen activator inhibitor (PAI-1) levels. These findings demonstrate a favourable effect of moxonidine on endothelial function. 23 Probably, this effect need not be so evident in patients without microalbuminuria, like in our patients in the early stages of hypertension. Furthermore, while not statistically different, the decrease in tissue plasminogen activator (t-PA) antigen, PAI-1 antigen, PAI-1 activity and fibrinogen was seen after 4 months of rilmenidine treatment in the obese hypertensives with hypertriglyceridaemia and impaired glucose tolerance. 24 Similarly, no statistically significant changes of fibrinogen were found in our hypertensive patients after 3-months treatment by rilmenidine.
It seems that there are differences between the antihypertensive agents in their effect on platelet function. From this viewpoint, the effect of centrally acting antihypertensive drugs has received only scant attention. In our hypertensive patients, the increased platelet aggregation (both SPA and APA) as well as plasma ␤TG were observed when compared to healthy subjects. In the present study, antihypertensive treatment by rilmenidine was shown to reduce platelet aggregation. This finding was evident already after 1 week, but mainly after 1 month, and after 3 months of therapy. It was also accompanied by a decrease of plasma ␤TG after 3 months of rilmenidine therapy. In fact, several mechanisms of the effect of rilmenidine on platelet function can be considered. Probably it is a result of its sympathoinhibitory and/or protective action on the arterial wall, but some platelet receptor binding mechanism cannot be excluded.
Different ␣ 2 -adrenoceptor subtypes mediate adenylate cyclase inhibition and adrenaline-stimulated aggregatory responses in human platelets. 25 Characterisation of the binding of clonidine analog to human platelet membranes has revealed multiple binding sites, indicative not only of ␣ 2 -adrenoceptor. 25 These non-adrenergic binding sites on human platelets are similar to a noradrenaline-insensitive binding sites with high affinity for imidazoline compounds (such as clonidine and its analogues), first observed in bovine brainstem. 26 Human platelets are shown to possess, besides an ␣ 2 -adrenoceptor, at
Journal of Human Hypertension least two high-affinity, imidazoline-preferring binding sites (subtype I 1 and subtype I 2 imidazoline receptor) that are pharmacologically distinct from ␣ 2 -adrenoceptors. 25, 26 . In vitro, moxonidine appears to induce a concentration-dependent platelet aggregation in healthy human subjects by an ␣ 2 -adrenergic-like mechanism, similar to the aggregation response to the ␣ 2 -adrenoceptor agonist adrenaline. 27 However, moxonidine has no effect on platelets at concentrations below 1.0 M, confirming its low potency at ␣ 2 -adrenergic receptors, that is 17-fold less than adrenaline. 27 However, moxonidine has no effect on platelets at concentrations below 1.0 M, confirming its low potency at ␣ 2 -adrenergic receptors, that is 17-fold less than adrenaline. 28 Moxonidine was found to bind with high affinity to I 1 sites on human platelet membranes. 26 The function of I 1 receptors on the platelet membrane, however, is not known. A specific I 1 receptor-mediated effect of moxonidine on platelet aggregation or the release reaction to various agonists could not be demonstrated. 27 Despite that, an imidazolinemediated effect of moxonidine on platelet inhibitory pathways cannot be ruled out. As suggested by some observations, I 1 receptors might still play a role in platelet physiology. 27 Platelets are serotonincontaining cells and its release is a critical step in the response of platelets to stimuli. A non-adrenergic, clonidine-induced inhibition of 5-hydroxyindolacetic acid concentrations was shown in serotonergic cell bodies. The existence of imidazoline receptors on platelets might thus explain certain atypical properties of clonidine which are not compatible with a pure ␣ 2 -adrenoceptor-mediated platelet aggregation. 26 Clonidine alone does not stimulate aggregation, but it is a weak agonist of the aggregation response to ADP, and an inhibitor of the aggregation response to adrenaline. 26 The fact that imidazoline compounds display either agonist or antagonist properties has led other investigators to conclude that certain imidazoline compounds may interact with additional 'non-␣ 2 -adrenoceptor sites' on platelets. Actually, some imidazolines behave as either pure ␣ 2 -adrenergic agonists or pure ␣ 2 -adrenergic antagonists, other act solely through non-␣ 2 -adrenoceptor mechanism. Thus, these complex findings are explained by the existence of non-adrenergic imidazoline binding sites on human platelets. 26 The exact function of the imidazoline binding sites on platelets, however, ought to be the subject of further studies.
The activation of SNS plays a role in the pathogenesis of essential hypertension and its inhibition is of a therapeutic value. 29 In the individuals with SNS activation plasma noradrenaline is higher than in normotensive controls. Sympathetic activation contributes not only to BP elevation, but it has been suggested to have adverse consequences beyond this, possibly contributing to the development of cardiovascular remodelling and atherosclerosis. 29 It may be central to all aspects of metabolic syndrome as the common denominator of the clustering of cardiovascular risk factors, which often occur in patients with high BP. 29 Drugs that diminish SNS activity may favourably affect all coronary risk factors. 8, 30 These favourable metabolic effects of rilmenidine, eg on lipids and insulin sensitivity, may translate into improved platelet function.
Drugs such as rilmenidine may regulate catecholamine release. 29 They dose-dependently reduce plasma noradrenaline, adrenaline and renin levels in man, a finding consistent with central inhibition of sympathetic tone. 8, 12, 28, 29 A reduction of catecholamine release is a further factor that can lead to a favourable effect on platelet function in patients with essential hypertension.
In conclusion, our study demonstrates a beneficial effect of rilmenidine therapy on endothelial and platelet function, in addition to its efficacy to normalise elevated BP. It can be concluded from this that potentially antithrombotic and vasculoprotective effect of rilmenidine may be important in terms of the favourable role of antihypertensive drugs in cardiovascular morbidity. Whether or not the theoretical potential positive effect of rilmenidine on cardiovascular risk factors will translate into tangible long-term clinical advantages for hypertensive patients needs to be assessed in specifically designed studies. However, on the available evidence, rilmenidine seems to be a logical choice for the treatment of these at-risk populations.
